Y-mAbs Highlights Key Investor Conferences This October
Y-mAbs Therapeutics Informs Participation in Key Investor Conferences
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), a prominent player in the biopharmaceutical industry, is enthusiastic about its upcoming participation in significant investor conferences. These events are crucial for the company as they emphasize innovative developments in radioimmunotherapy and antibody-based treatments targeted at combating cancer.
Overview of Upcoming Conferences
The management team at Y-mAbs will be engaged in two noteworthy conferences on the very same day, aimed at exploring advanced therapeutic strategies in oncology.
Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit
On Tuesday, October 8, Y-mAbs will have a platform at the Oppenheimer Summit, scheduled to commence at 9:30 a.m. ET. This event is set to focus on the session "The Next Wave of TRTs – Targets, Targeting Technologies and Isotopes". Such discussions will delve into emerging trends and targeted therapies that may reshape the treatment landscape for cancer patients.
BMO Oncology Summit
Later on the same day, the company will transition to the BMO Oncology Summit, where a fireside chat titled "Shifting the Antibody Paradigm" will take place at 3:00 p.m. ET. This dialogue is anticipated to shed light on the evolving role of antibodies in oncological applications, showcasing Y-mAbs’ commitment to groundbreaking solutions in the fight against cancer.
About Y-mAbs and Their Innovative Approach
Y-mAbs Therapeutics specializes in the creation and commercial distribution of state-of-the-art therapeutic products primarily aimed at cancer treatment. Their innovative technology portfolio includes the Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and unique bispecific antibodies produced via the Y-BiClone platform.
The company boasts a diverse and advanced pipeline of products, including DANYELZA® (naxitamab-gqgk), which has garnered FDA approval as the first treatment for patients battling relapsed or refractory high-risk neuroblastoma. This treatment showcases the company's commitment to providing effective solutions for pediatric patients facing tough prognoses.
Investor Relations and Contact Information
For those interested in the company's advancements or investor inquiries, Y-mAbs encourages reaching out to their investor relations team. Courtney Dugan, Vice President and Head of Investor Relations, is available for any inquiries related to business strategies, investor updates, and more.
Contact Information:
Courtney Dugan
VP, Head of Investor Relations
Email: cdu@ymabs.com
Frequently Asked Questions
What is Y-mAbs Therapeutics, Inc. known for?
Y-mAbs Therapeutics is known for its dedication to developing innovative therapies, especially in the field of cancer treatment through radioimmunotherapy and antibody-based approaches.
Why are the upcoming conferences important for Y-mAbs?
The conferences provide a platform for Y-mAbs to share insights on their advancements and engage with potential investors, enhancing visibility and opportunities in the industry.
What is DANYELZA® and its significance?
DANYELZA® is the first FDA-approved drug for treating relapsed or refractory high-risk neuroblastoma, highlighting Y-mAbs’ pivotal role in pediatric oncology.
Who can be contacted for investor inquiries?
Investors can contact Courtney Dugan, the VP of Investor Relations at Y-mAbs, via the provided email for any queries.
When will Y-mAbs participate in the investor conferences?
Y-mAbs will participate in the aforementioned conferences on October 8, where their management team will present and engage in discussions regarding their products and innovations.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Essential Nutrition Strategies for Hunting Dogs This Season
- Barclays Highlights Potential Earnings Challenges for Big Tech
- Petra Funds Group Expands Team with Key Leadership Roles
- Key Disclosure of Rathbones Group Plc's Interest in Balanced Commercial Property Trust
- Glucotrack Unveils Key Innovations at Upcoming Diabetes Conference
- Understanding Recent Disclosures by Keywords Studios Plc
- Exploring AI in Healthcare: Key Insights and Perspectives
- Berkshire Partners Directors Recognized Among Top Investors
- State Street's Planned Senior Notes Redemption: Key Insights
- NewLake Capital Partners Gears Up for Major October Conferences
Recent Articles
- Exciting Insights Ahead: Herbalife's Q3 2024 Results Preview
- QuantaSing's New Special Dividend Set to Reward Shareholders
- Laser Photonics Partners with Hemlock Semiconductor for Innovation
- Codexis Partners with Alphazyme to Enhance Enzyme Solutions
- Emcore Corporation Evaluates Purchase Proposal from Mobix Labs
- Sandy Spring Bancorp to Host Earnings Call for Q3 Results
- Health Assurance Foundation Teams Up to Enhance Healthcare Access
- Calian and Walmart Canada Team Up for Enhanced Pharmacy Services
- IBM's Nickle LaMoreaux Earns Prestigious HR Executive Title
- Innovative Collaboration Between Japan Tobacco and D-Wave on Drug Discovery
- OPTEL and Worximity Collaborate to Enhance Operational Efficiency
- Adeia and VIZIO Collaborate in a Strategic IP License Renewal
- Chemomab Therapeutics to Engage Investors in October Conferences
- STP Launches Innovative BluePrint Platform for Investment Firms
- Jennifer Cable Joins J2 Ventures Advisory Board to Drive Innovation
- Marex Expands Global Reach with Dropet Biofuels Acquisition
- Simply Good Foods Prepares to Share Financial Results Soon
- Pebblebrook Hotel Trust Unveils 2024 Sustainability Achievements
- Legal-Bay Launches Informative Q&A Webpage for Plaintiffs
- Foghorn Therapeutics: Transforming Oncology at Upcoming Summit
- InspiroGene by McKesson: Revolutionizing Cell and Gene Therapies
- Valens Semiconductor Launches Advanced VA7000 and VS6320 Chipsets
- Canadian Solar's e-STORAGE Revolutionizes Energy in Chile
- Intertek Launches Innovative Global Compliance Service
- InMode Restructures Leadership for Strategic Growth Initiatives
- Revolutionizing Travel Safety: BOXX Insurance's Cyber Solution
- Dentalcorp: Celebrating Success as a Top Growing Company in Canada
- BOXX Insurance and World Travel Protection Launch Cyber Assist
- RedHill's Talicia® Secures Ongoing Access for Millions in California
- Meketa Investment Group Achieves Milestone Growth with New Team
- Sealed Air Welcomes Anthony Allott to Board of Directors
- Willis Lease Finance Corporation’s Major Preferred Stock Deal
- EmGenisys Wins $250,000 Grand Prize at BioTools Innovator
- FDA Fast Tracks Zilganersen for Treating Alexander Disease
- Colliers International Extends Leadership Contract with CEO
- Sara Egan Joins SignaPay as New Vice President of Sales
- Y-mAbs Therapeutics to Shine at Upcoming Investor Conferences
- Enbridge's Acquisition of PSNC Enhances U.S. Gas Utilities Growth
- Meta to Boost Virtual Reality Production in Vietnam by 2025
- Canadian Solar's e-STORAGE to Support Huatacondo Project Growth
- Pakistan's Inflation Rate Drops to New Low Amid Economic Reforms
- Apriori Bio Welcomes Harry Kleanthous as New CSO
- Akamai Technologies Plans Investor Call for Q3 Financials
- September Rally Lays Groundwork for SPX Gains Ahead
- Market Sentiment Shifts as US Indices Show Bullish Trends
- MRS Logística Chooses Iridium Certus for Enhanced Connectivity
- Garmin Launches Fusion Apollo Marine Audio Series for Boaters
- Silexion Therapeutics Advances SIL-204 for KRAS Cancer Treatment
- EDEN Highlighting Innovations at the Upcoming Service World Expo
- WESCO International Positioned for Growth Amid Positive Outlook